Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the first anti-CD38 therapy with VRd to significantly reduce disease progression or death by 40%.
Sarclisa Approved for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant.
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...
Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback